Affirming support for most-favored-Nation drug pricing for United States patients.

This resolution expresses the House of Representatives' support for most-favored-nation drug pricing, which aims to ensure that U.S. patients pay no more for prescription drugs than patients in other developed nations. It cites studies showing U.S. drug prices are nearly 2.78 times higher than in other countries and that many Americans skip or cut doses due to cost. The resolution references a May 2025 executive order by President Trump and subsequent letters to pharmaceutical manufacturers to align U.S. drug prices with the lowest prices in other developed nations. The House resolves to support the principle that U.S. patients should not be charged more than those in other countries for the same drugs, and affirms commitment to reducing drug costs through policies that align U.S. pricing with other developed nations, expanding Medicare drug price negotiation, and promoting price competition.